With 1,600 active life sciences companies employing 83,000 people, Israel is home to a vibrant medical innovation ecosystem. Leveraging its strengths in relevant fields like artificial intelligence, medical devices, digital health, and R&D, the Startup Nation has pioneered some of medicine’s most exciting breakthroughs – from PillCam, a noninvasive colonoscopy alternative, to ReWalk, a robotic exoskeleton designed to enable mobility for the disabled.
Israel’s prowess in the medical field will be on display for the estimated 120,000 visitors slated to attend the Medica trade fair in Dusseldorf, Germany, from Nov. 18-21. Together with the Israel Export Institute, the Ministry of Economy and Industry’s Foreign Trade Administration will host a national pavilion featuring more than 70 Israeli companies whose work spans the spectrum of healthcare innovation, from medical devices to diagnostics to pharmaceuticals and everything in between.
The conference, which has now been taking place for more than 40 years, will feature 5,100 exhibitors from 70 countries across the globe, and will offer exhibiting companies exposure to international networks of medical entrepreneurs, physicians, hospital executives, researchers, and more.
Here’s a look at just a few of the Israeli companies set to showcase their solutions:
- Nasdaq-traded CollPlant Biotechnologies is a regenerative medicine company specializing in the 3D printing of human tissues and organs. A leader in the field of wound treatment and organ and tissue repair, the company made headlines in 2018 for its partnership with United Therapeutics for the licensing, development, and commercialization of 3D bioprinted lung transplants.
- More than a quarter billion people worldwide suffer from chronic obstructive pulmonary disease, which accounts for an estimated 5 percent of all global deaths. Those living with COPD suffer severe breathing complications that can significantly degrade quality of life – but Respinova’s PulseHaler technology aims to help by mitigating small airway collapse in COPD patients. The noninvasive device opens the airways by generating pulses of pressure that also help ease exhalation and smoothen airway walls, which can help prevent re-closing of the airways.
- Early detection is vital to improving survival rates for cancer, and Nucleix is at the forefront of the effort to save patient lives through its innovative technology. In 2018, the European Union awarded the company $2.9 million in funding for Lung EpiCheck, a diagnostic blood test that aims to boost early detection of lung cancer. A clinical study found that the company’s test generated 70 percent accurate identification for non-small-cell lung cancer, with 59 percent accurate identification for stage I patients, and 92 percent accurate identification for small cell lung cancer. Nucleix has also released Bladder EpiCheck, which monitors for recurrence of bladder cancer, which has a high recurrence rate.
For Medica attendees, these and the other exhibiting Israeli companies offer testimony to the ingenuity and innovation of Israel’s medical technology sector. For people worldwide, they offer hope for saving lives – and dramatically improving the quality of life for millions more.
To schedule a meeting, click here
For more details on the Israeli pavilion, click here
For more information, please contact us at Sydney@israeltrade.gov.ill